Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Sarcopenia, the systemic loss of skeletal muscle mass and function, is prevalent and particularly detrimental to head and neck cancer (HNC) patients. Cancer-associated sarcopenia involves complex mechanisms of poor nutrition and inflammation, highlighting the necessity for preoperative identification of these high-risk patients.

Methods: A multi-site retrospective chart review (2016-2021) was performed on HNC patients undergoing total laryngectomy with or without reconstruction. Preoperative lab values were utilized to calculate markers of sarcopenia including systemic immune inflammation index (SII), nutrition-related index (NRI), geriatric NRI (GNRI), and neutrophil-to-lymphocyte ratio (NLR). Comparative analyses, ROC curves, and logistic regressions were conducted to evaluate the predictive value of these indices on 30-day postoperative outcomes.

Results: In a cohort of 520 laryngectomy patients (75.8% salvage), postoperative fistula, major complication, and prolonged PO intake > 30 days were recorded in 22.7%, 25.4%, and 26.2% of patients, respectively. NLR was higher in patients with prolonged PO intake, while the NRI/GNRI was lower in patients with delayed PO intake. There were no significant differences in patient indices with or without fistula and major complications. All nutritional indices on ROC curves had areas under the curve < 0.600. After adjusting for confounding on multivariate logistic regression, the NLR (OR = 0.95) and SII (OR = 0.98) were predictive of major postoperative complications, while the NRI/GNRI (OR = 0.96) was predictive of delayed PO intake.

Conclusions: Nutritional indices may be valuable to predict adverse postoperative laryngectomy outcomes. Prospective studies are needed to validate these findings.

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.28110DOI Listing

Publication Analysis

Top Keywords

markers sarcopenia
8
patients undergoing
8
hnc patients
8
roc curves
8
fistula major
8
prolonged intake
8
patients
7
biochemical markers
4
sarcopenia
4
sarcopenia predictors
4

Similar Publications

Clinical, Immunological, and Vesicular Markers in Sarcopenia and Presarcopenia.

Front Biosci (Landmark Ed)

August 2025

Division of Biochemistry and Molecular Biology, Siberian State Medical University, Ministry of Health of the Russian Federation, 634050 Tomsk, Russia.

Background: Sarcopenia is a complex, multifactorial condition characterized by progressive loss of muscle mass, strength, and function. Despite growing awareness, the early diagnosis and pathophysiological characterization of this condition remain challenging due to the lack of integrative biomarkers.

Objective: This study aimed to conduct a comprehensive multilevel profiling of clinical parameters, immune cell phenotypes, extracellular vesicle (EV) signatures, and biochemical markers to elucidate biological gradients associated with different stages of sarcopenia.

View Article and Find Full Text PDF

Background: Musculoskeletal disease (MSD), including osteoarthritis, rheumatoid arthritis, osteoporosis, and sarcopenia, poses a serious social burden. While physical activity (PA) benefits musculoskeletal health, the optimal PA level for MSD prevention remains unclear. Clarifying risk factors and biological mechanisms is essential.

View Article and Find Full Text PDF

Background And Aims: Sarcopenia, characterized by age-related loss of muscle mass and function, increases adverse outcomes in older adults. The predicted skeletal muscle mass index (pSMI), derived from serum creatinine and cystatin C, may serve as a practical biomarker. This study evaluated pSMI's ability to predict sarcopenia and mortality in older Chinese adults.

View Article and Find Full Text PDF

ObjectiveSarcopenia poses a significant global public health burden, underscoring the urgency of identifying reliable risk markers for early detection and intervention. This study aimed to elucidate the association between the neutrophil-to-high-density lipoprotein cholesterol ratio and sarcopenia as well as explore how various covariates modify this relationship.MethodsA cross-sectional analysis was performed using data from 9040 individuals who participated in the National Health and Nutrition Examination Survey 2011-2018, of whom 721 were diagnosed with sarcopenia.

View Article and Find Full Text PDF

Therapeutic potential of sulfasalazine for sarcopenia: Insights from mouse models and clinical data.

Exp Gerontol

September 2025

Mitos Biomedical Institute, Mitos Therapeutics Inc., Daejeon, Republic of Korea; Department of Pharmacology and Medical Science, College of Medicine, Chungnam National University, Daejeon, Republic of Korea. Electronic address:

Sarcopenia, a disease marked by a progressive loss of muscle mass, increases the risks of disability and metabolic disorders, and decreases quality of life. Current therapeutic options are limited. YY1 transcriptional activity is augmented through an interaction with PHF20 at its promoter region, suppressing muscle differentiation.

View Article and Find Full Text PDF